Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Keith Kaye

General ID · RU

View

Dr. Rochelle Walensky

General ID · Harvard Medical School

View

Dr. Erin Bonura

General ID · OHSU

View

Dr. Nizar Wehbi

General ID

View

Dr. Robert Schooley

General ID · UCSD

View

Dr. Priya Nori

General ID · MMC

View

Dr. Jan Patterson

General ID · UTHSCSA

View

Dr. Kavita Bhavan

General ID · Dallas County Hospital District

View

Dr. John Goldman

General ID · UPMC Central PA

View

Dr. Gonzalo Bearman

General ID · Medical College of Virginia

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Antibiotic Duration after Debridement and Implant Retention for Early Postoperative Spinal Implant Infections: A Multicenter Cohort Study.

    May 5, 2026DOI: 10.1093/cid/ciag300Journal ArticleCID

    Written by: Don Bambino Geno TaiEmily PoehleinJessica C O'NeilSandra B NelsonAaron J TandeDaniela De Lima CorvinoAlaina S RitterJenny AronsonLaura CertainDaisuke FurukawaAlexander M TataraCynthia L GreenTarek AbdallaMolly E FleeceDaniel G TobertMelissa EricksonJessica SeidelmanSPIRIT Team

    Find these authors on Roon

    GT
    Dr. Geno Tai
    General ID · University of Minnesota

    Summary

    BACKGROUND: Postoperative spinal implant infections (PSII) are a serious complication of instrumented spinal fusion. Although debridement with implant retention is standard for early infection, the optimal duration of antimicrobial therapy remains uncertain.METHODS: We conducted a multicenter retrospective cohort study across ten U.S. academic centers, including adults with early PSII (≤90 days after fusion surgery) from 2017 to 2021. We excluded patients who experienced treatment failure within 6 weeks of debridement. The primary outcome was treatment failure. Antibiotic therapy effect was analyzed as a time-varying exposure using adjusted Cox proportional hazards models. Secondary analyses included 12-week landmark and clone-censor-weighted models to compare durations ≤12 weeks versus >12 weeks.RESULTS: 116 patients out of 499 (23.2%) experienced treatment failure during a median follow-up of 3.2 years. Among patients who remain failure-free six weeks from debridement, being on antibiotics was not associated with treatment failure (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.48-1.07; p = 0.10). In a 12-week landmark analysis limited to 359 patients who were not on indefinite suppressive antibiotic therapy, treatment durations >12 weeks did not significantly reduce the risk of failure (aHR 1.01, 95% CI 0.62-1.64; p = 0.99). Results were consistent in the clone-censor-weight sensitivity analysis (aHR 0.85, 95% CI 0.62-1.16; p = 0.30).CONCLUSIONS: Prolonged antibiotic therapy was not associated with improved outcomes in early PSII managed with debridement and implant retention. These results support shorter, individualized antibiotic courses in patients with adequate surgical source control.
    GTDr. Geno Tai

    Dr. Geno Tai

    Infectious Disease · General Infectious Disease
    University of Minnesota
    donbambinogeno